Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial CancerBusiness Wire • 05/18/26
Will Keytruda Continue to Aid MRK's Growth in 2026 After a Strong Q1?Zacks Investment Research • 05/13/26
Merck Highlights New Long-Term Data and Advancements Across Broad Oncology Portfolio and Pipeline Research at ASCO 2026Business Wire • 05/12/26
The Zacks Analyst Blog UnitedHealth, Merck & Co., Qualcomm, EVI and OptexZacks Investment Research • 05/12/26
Merck Scientists Publish Landmark Paper on Novel Method for Large-Scale Biocatalytic Synthesis of Investigational Oral PCSK9 Inhibitor, Enlicitide DecanoateBusiness Wire • 05/07/26
6 Pharma Dividend Stocks Yielding Up to 6.44% — and They've Survived Every Market Crash24/7 Wall Street • 05/06/26
Merck Animal Health Selects Salesforce's Agentforce Life Sciences for Customer Engagement to Transform Animal Care and Enhance Support Experiences for EmployeesBusiness Wire • 05/06/26
Merck Stock Looks Undervalued as KEYTRUDA Growth and Pipeline Offset Near-Term Headwinds24/7 Wall Street • 05/05/26
Warren Buffett Owns 2 of the Small Dogs of the Dow: Here's Why You Need to Own All 524/7 Wall Street • 05/04/26
Merck: 'Strong Buy' - Terns Acquisition And Ability To Counter Keytruda Patent LossSeeking Alpha • 05/03/26
MRK Q1 Earnings & Sales Beat Estimates, 2026 Sales View TightenedZacks Investment Research • 04/30/26
Merck (MRK) Q1 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks Investment Research • 04/30/26